SyntheticMR’s Receives Regulatory Clearance for SyMRI in the UK

SyntheticMR announced today that their quantitative imaging software solution SyMRI has received regulatory clearance in the UK. It can now be sold and distributed in this market.

“It’s very exciting to see our company’s continued growth. This regulatory clearance is one step closer to making SyMRI available all over the globe.” says Kyle Frye, CCO of SyntheticMR. “We look forward to bringing SyMRI to the UK market and to show how it can transform the clinical workflow in this region and become the standard of care.” 

SyMRI NEURO is a quantitative imaging software solution that measures the absolute tissue properties of the brain. SyMRI NEURO provides automatic segmentation of tissue such as myelin volumes, quantification of white matter, gray matter, cerebrospinal fluid and brain parenchymal volume. It is designed to help save valuable time by reducing scan time, all the while aiding as an objective decision support for diagnosis and patient follow-ups.  
 
SyMRI MSK produces quantitative T1, T2, and PD maps and a series of contrast-weighted images in a single fast scan, for both clinical use and advanced research. SyMRI MSK also makes it possible to change echo time (TE), repetition time (TR), and inversion delay (TI) post-scan.